首页> 外文期刊>International Journal of Nanomedicine >A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance
【24h】

A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance

机译:紫杉醇和达沙替尼的简单还原敏感性胶束共同给药可克服肿瘤的多药耐药性

获取原文
获取外文期刊封面目录资料

摘要

Multidrug resistance (MDR) is one of the major obstacles in successful chemotherapy. The combination of chemotherapy drugs and multidrug-resistant reversing agents for treating MDR tumor is a good strategy to overcome MDR. In this work, we prepared the simple redox-responsive micelles based on mPEG-SS-C18 as a co-delivery system to load the paclitaxel (PTX) and dasatinib (DAS) for treatment of MCF-7/ADR cells. The co-loaded micelles had a good dispersity and a spherical shape with a uniform size distribution, and they could quickly disassemble and rapidly release drugs under the reduction environment. Compared with MCF-7 cells, the DAS and PTX co-loaded redox-sensitive micelle (SS-PDNPs) showed stronger cytotoxicity and a more improving intracellular drug concentration than other drug formulations in MCF-7/ADR cells. In summary, the results suggested that the simple co-delivery micelles of PTX and DAS possessed significant potential to overcome drug resistance in cancer therapy.
机译:多药耐药性(MDR)是成功化疗的主要障碍之一。化疗药物和多药耐药逆转剂联合治疗MDR肿瘤是克服MDR的好策略。在这项工作中,我们准备了基于mPEG-SS-C 18 作为共同递送系统的简单氧化还原反应性胶束,以装载紫杉醇(PTX)和达沙替尼(DAS)用于治疗MCF- 7 / ADR电池。共载胶束具有良好的分散性和球形,尺寸分布均匀,在还原环境下可以快速分解并快速释放药物。与MCF-7细胞相比,与MCF-7 / ADR细胞中的其他药物制剂相比,DAS和PTX共同负载的氧化还原敏感胶束(SS-PDNPs)具有更强的细胞毒性和更高的细胞内药物浓度。总之,结果表明,PTX和DAS的简单共递送胶束具有克服癌症治疗中耐药性的巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号